LongShort Momentum · 2026-10-24 · beta
The week's thesis map largely stands — the power order was not placed, and hepatitis B did not enlarge who enters care
U.S. cash markets are closed. The week's thesis map largely stands and did not strengthen. Venture Global's 15 October frame with GE Vernova and Baker Hughes was restated through the week; the first power-island purchase order was not placed. Sterling remains on turbines, with the Golden substation vote moved to 5 November and not yet taken. Sangdong tonnes, a Los Santos shipment, a Springer close, and a Hemerdon offtake did not appear. GSK's Hibsago approval of 20 October stands for patients already on antivirals; no price or prescribing count followed. Pattern-hair-loss expansion, a second RAS tumor, cheap-intercept quantities beyond Coyote and LIDS, and a new Treasury buyback did not appear. No candidate promoted in this hunt cycle.
U.S. equity and credit cash markets are closed. This is a weekend judgment of the week that ended Friday, not a cash session. The week's thesis map largely stands. It did not strengthen. The failure that matters is the first power-island purchase order. Headlines that described an off-grid network in south Louisiana restate Venture Global's 15 October release: frame agreements with GE Vernova and Baker Hughes Energy Services for up to 16 units of 720 megawatts. The company still expects the first purchase order by the end of 2026. That order was not placed. Up to 10 gigawatts of compute by the end of 2034 remains conditional on customer commitments. Vantage's VA2 campus in Sterling is still on natural gas turbines, because Dominion has a years-long hold on large-user power. On 21 October the Loudoun board voted 8 to 0, one supervisor absent, to move the Golden substation item from 1 December to 5 November. That motion does not decide the 5 November vote. Dominion described a partial supply by the end of 2028 that would not move the campus ahead in the large-load queue. Megawatts were not stated. The vote has not been taken. A Kentucky decision on Muskie, a final Electric Reliability Council of Texas Batch Zero allocation, and a named utility connection already in service did not appear. An SLB item on Kelvion is a cooling transaction that was not opened to a filing. It is not a switchgear order. A note on SLB data-center revenue was not opened, so no figure from it is used. TES Power's added capacity in Northern Ireland is a factory abroad, not this purchase order.
## Tonnes stayed ahead of the headlines
Sangdong quantities, a Los Santos restart and first shipment, a Springer close, and a U.K. offtake for Hemerdon did not appear. Public capital and commercial offtake remain ahead of delivered tonnes. Friday's AD HOC NEWS headline on Almonty describes a dated cargo and the gap between a running mine and delivery. It was not opened to a company filing. A Diamond Equity note is commentary. NioCorp's commercial-sales statement is a different project. A 15 October local report of Department of War money for a nickel-copper project at Baraga Basin was not opened to a department release, so the dollar figure is not adopted.
## Chronic hepatitis B did not enlarge who enters care
**Condition.** Chronic hepatitis B in adults already on antivirals, without cirrhosis, under a low surface-antigen cutoff. **Company, drug, and stage.** GSK's Hibsago (bepirovirsen), licensed from Ionis, was approved by the FDA on 20 October 2026. Roche's Elecsys surface-antigen assay was authorized with it. In the agency's trial summary, 19 percent of treated patients still had the virus controlled 24 weeks after all treatment stopped, against none in the placebo group. The label carries a boxed warning for serious liver reactions and low platelets. **Expansion versus share shift.** Neither. The course can shorten therapy for a minority of people already in care. It does not show a larger group entering care. A U.S. price, a launch, and a prescribing count did not appear. Filings for GSK, Ionis, and Roche were not tested as a new basket. The approval is the week's clearest new fact, and use did not follow it.
## Pattern hair loss is still an unproven expansion
**Condition.** Androgenetic alopecia. Female pattern hair loss was not split into its own case. **Company, drug, and stage.** Veradermics (MANE) is developing oral VDPHL01 in registration-directed Study 304, guided to the second half of 2026. Cosmo (COPN) has completed Phase III for topical clascoterone, with a U.S. filing path aimed at early 2027. Absci (ABSI) has ABS-201 in the clinic. The interim already on file was not replaced. **Expansion versus share shift.** The question is whether a safer or easier drug pulls in people outside today's finasteride and minoxidil use. Moving those current users would be share shift. The search returned older company updates, not Study 304, a Cosmo filing, a new Absci interim, or a prescription count. Development capital already raised stays confirmed and is not a new financing. Second-quarter filings versus the first cover Veradermics and Absci only. They are lagged. Cosmo was outside that set. Those filings are not a prescription count, and they are not a reason to start the thesis.
## What else held
Daraxonrasib, from Revolution Medicines, remains a single labeled use in metastatic pancreatic cancer. Casdatifan, from Arcus, is a HIF-2α drug in clear-cell kidney cancer, not this label. Betta's BPI-572270 remains a 7 October U.S. trial clearance for a competing approach, not an approval. Ownership was queried for Revolution Medicines alone. Inexpensive intercept has no order with quantities beyond the Raytheon Coyote and LIDS award of $729 million already recorded. A request to scale autonomous weapons is not that order. Taiwan items were older political notes, not an appropriation through NT$40 billion. Patriot and Terminal High Altitude Area Defense (THAAD) remain the industrial print that recurs. The monetary frame remains the Treasury long-end buyback expansion of 19 August 2026. Central-bank gold headlines were not adopted. No prices were used. Quarterly gold ownership is mixed and lagged. Starboard's 20 October stake in Solstice is a shareholder item, not a breakdown. A report of nominations at Knife River is attributed to sources and was not opened to a filing.
## Outside the book
**Mismatch-repair-deficient rectal cancer.** GSK's Jemperli (dostarlimab) received accelerated approval on 19 October for previously untreated stage II or III disease in that group. A consumer story about one patient is the same approval as an anecdote. One narrow use is not a multi-program expansion of a chronic undertreated population, and it is not a second pancreatic tumor. **Hormone receptor-positive breast cancer.** Entinostat plus exemestane, in the 20 October survival update, showed overall survival numerically longer and not statistically significant, on a regimen described as already approved in China. It does not clear. **Menopausal hormone therapy.** A once-weekly generic of Climara Pro, approved 20 October, is a more convenient form of an existing therapy. Read it as share shift unless uptake shows otherwise. **Spinocerebellar ataxia.** Biohaven (BHVN), Vyglxia (troriluzole), remains a resubmission accepted on 22 October, with a user-fee goal in the first quarter of 2027 and an advisory committee still undated. It is not approved. The weekend wire adds no meeting date. **Solar finance in Batangas.** Citicore headlines describe a syndicated loan. The borrower filing was not opened, so the amount is not adopted. It is not a U.S. connection and not a mineral shipment. No candidate promoted in this hunt cycle. Preprint servers and patent feeds were not in this scheduled search.
## What carries into next week
Pattern hair loss remains an early bridge without evidence that more people are being treated. Hibsago remains a labeled add-on without a price or a prescription count. Cheap intercept remains the Coyote and LIDS quantity. The pancreatic label remains a single use. Gold remains the recognized hedge. AI and site power, critical minerals, and defense stay strengthening. Healthcare and the consumer reading on hair loss stay emerging. Distress and the wildcard lane stay dormant.
## What should happen next
The first power-island purchase order, or a year-end with that order unplaced. Loudoun's vote on 5 November. A Kentucky decision on Muskie, a final Batch Zero allocation, or a connection already in service. A company disclosure of Sangdong tonnes, a Los Santos shipment, a Springer close, or a Hemerdon offtake. Study 304, a Cosmo filing, or evidence that previously untreated people start hair-loss treatment. A Hibsago price or prescribing count. The date of Biohaven's advisory committee, which stays off the book until the review says more than an acceptance.
## What would invalidate
No purchase order by the end of the frame window, a denied Golden substation, or a 2028 supply that produces no power. A hair-loss Phase 3 miss, a safety block, or a launch that only moves share. Patients who start Hibsago and remain on antivirals. A daraxonrasib label that never leaves pancreatic cancer. No follow-on cheap-intercept quantities while Patriot and Terminal High Altitude Area Defense (THAAD) remain the print that recurs. Financed mines that fail to ship. A Treasury buyback regime withdrawn without a replacement.
Independent research — not investment advice.
